Unknown

Dataset Information

0

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.


ABSTRACT: Background:The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review. Patients and methods:Patients were randomized to 3 cycles of D followed by 3 cycles of FEC (D-FEC),?±4 cycles of Bev (Bev?+?D-FEC). DFS and OS were analyzed by treatment and by central pathology reviewed pCR and Residual Cancer Burden (RCB) class. Results:A total of 800 patients were randomized [median follow-up 3.5 years (IQR 3.2-4.4)]. DFS and OS were similar across treatment arms [DFS hazard ratio (HR)=1.18 (95% CI 0.89-1.57), P?=?0.25; OS HR?=?1.26 (95% CI 0.90-1.76), P?=?0.19). Both local pathology report review and central histopathology review confirmed a significant improvement in DFS and OS for patients who achieved a pCR [DFS HR?=?0.38 (95% CI 0.23-0.63), P?

SUBMITTER: Earl HM 

PROVIDER: S-EPMC5834079 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

Earl H M HM   Hiller L L   Dunn J A JA   Blenkinsop C C   Grybowicz L L   Vallier A-L AL   Gounaris I I   Abraham J E JE   Hughes-Davies L L   McAdam K K   Chan S S   Ahmad R R   Hickish T T   Rea D D   Caldas C C   Bartlett J M S JMS   Cameron D A DA   Provenzano E E   Thomas J J   Hayward R L RL  

Annals of oncology : official journal of the European Society for Medical Oncology 20170801 8


<h4>Background</h4>The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review.<h4>Patients and methods</h4>Patients were randomized to 3 cycles of D followed by 3 cycles of FEC (D-FEC), ±4 cycles of Bev (Bev +  ...[more]

Similar Datasets

| S-EPMC2799234 | biostudies-literature
| S-EPMC7103001 | biostudies-literature
| S-EPMC8144560 | biostudies-literature
| S-EPMC6298890 | biostudies-literature
| S-EPMC3399644 | biostudies-literature
| S-EPMC5824321 | biostudies-literature
| S-EPMC3494422 | biostudies-literature
| S-EPMC9264845 | biostudies-literature
| S-EPMC6202826 | biostudies-literature
| S-EPMC4176878 | biostudies-literature